Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM67VKL)

• Drug Name: Prasterone Drug Info
• Synonyms: Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Phase 4	[2]

• Cross-matching ID:
  PubChem CID: 5881
  ChEBI ID: CHEBI:28689
  CAS Number: CAS 53-43-0
  TTD Drug ID: DM67VKL
  VARIDT Drug ID: DR01193
  INTEDE Drug ID: DR0431

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[23]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[24]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[25]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[26]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[27]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[28]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[29]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[30]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[31]
Fluoxymesterone	DMUHCF1	Breast cancer	2C60-2C65	Approved	[32]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[17]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[17]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[153]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[154]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[155]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[156]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[157]
Selenium	DM25CGV	N. A.	N. A.	Approved	[158]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[160]

Drug(s) Targeting Glucose-6-phosphate dehydrogenase (G6PD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EPIANDROSTERONE	DM08XIN	N. A.	N. A.	Phase 3	[33]
CBF-BS2	DM2FAH0	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[34]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[35]
Hydroxyacetic Acid	DMQFBH6	Discovery agent	N.A.	Investigative	[35]
Metazamide	DMQBGH9	Discovery agent	N.A.	Investigative	[4]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[37]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[38]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[40]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[41]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[42]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[43]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[44]

Drug(s) Transported By Multidrug resistance-associated protein 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[46]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[47]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[48]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[7]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[49]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[51]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[7]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[52]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[54]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[55]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[56]
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[57]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[58]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[59]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[60]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[61]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[62]

Drug(s) Transported By Multidrug resistance-associated protein 8 (ABCC11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[63]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[64]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[65]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[66]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[9]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[67]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[69]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[70]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[71]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[72]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[73]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[74]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[127]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[128]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[129]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[130]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[131]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[131]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[132]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[133]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[134]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[135]

Drug(s) Metabolized By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[75]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[76]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[77]
Levomethadyl acetate hydrochloride	DM429AE	N. A.	N. A.	Approved	[78]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[79]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[80]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[81]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[82]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[82]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[83]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[82]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[82]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[82]
Metronidazole	DMTIVEN	Abscess		Approved	[84]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[136]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[137]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[138]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[139]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[140]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[141]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[142]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[143]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[144]

Drug(s) Metabolized By Sulfotransferase 2A1 (SULT2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abiraterone acetate	DMANBZI	Prostate cancer	2C82.0	Approved	[86]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[87]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[15]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[88]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[13]
BCP-13498	DM2BO9W	N. A.	N. A.	Phase 2	[89]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[13]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[13]
Tetramethylbutylphenol	DMW9CH2	N. A.	N. A.	Investigative	[13]
N-nonylphenol	DMH3OUX	N. A.	N. A.	Investigative	[13]

Drug(s) Metabolized By Dihydrotestosterone oxidoreductase (HSD3B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[90]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[91]
HE2100	DMCP2KH	Thrombocytopenia	3B64	Discontinued in Phase 1	[14]
17alpha-hydroxypregnenolone	DMT2EPG	Discovery agent	N.A.	Investigative	[91]

Drug(s) Metabolized By Beta-HSD adrenal and gonadal type (HSD3B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[90]
Norethindrone acetate	DMDGCQP	N. A.	N. A.	Approved	[92]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[91]
17alpha-hydroxypregnenolone	DMT2EPG	Discovery agent	N.A.	Investigative	[91]

Drug(s) Metabolized By Peroxisomal multifunctional enzyme 2 (HSD17B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[14]

Drug(s) Metabolized By Sulfotransferase 2B1 (SULT2B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[15]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[145]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[146]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[147]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[148]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[149]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[150]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[151]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[152]

Drug(s) Metabolized By Estradiol 17-beta-dehydrogenase 2 (HSD17B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[14]

Drug(s) Metabolized By Cytochrome P450 7B1 (CYP7B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hombreol	DMZYB3S	N. A.	N. A.	Investigative	[16]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[119]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[120]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[121]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[122]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[123]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[121]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[124]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[125]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[126]

Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[14]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[98]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[99]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[100]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[101]

Drug(s) Affected By Peroxisomal multifunctional enzyme type 2 (HSD17B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[14]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[103]
Haloperidol	DM96SE0	Delirium		Approved	[104]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[108]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[109]

Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Metyrapone	DMI7FVQ	Cushing disease	5A70	Approved	[112]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[113]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[114]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[115]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[116]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[114]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[117]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[14]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[161]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[162]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[163]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[164]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[165]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[166]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[167]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[168]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[169]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[170]

Drug(s) Affected By Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[171]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[172]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[173]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[174]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[175]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[176]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[177]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[177]
ABIRATERONE	DM8V75C	Prostate cancer	2C82.0	Approved	[178]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[179]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[180]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[180]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[180]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[181]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[182]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[183]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[184]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[185]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[186]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[187]

Drug(s) Affected By Anterior gradient protein 2 homolog (AGR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[148]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[188]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[189]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[99]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[190]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[191]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[192]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[193]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[194]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[195]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[196]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[197]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[198]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[194]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[199]

Drug(s) Affected By Glucocorticoid receptor (NR3C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[200]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[201]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Selenium	DM25CGV	N. A.	N. A.	Approved	[202]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[203]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[204]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[205]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[206]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[207]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[208]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[209]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[210]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[211]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[212]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[213]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[214]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]

Drug(s) Affected By Transcription factor Jun (JUN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[216]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[217]
Fructose	DM43AN2	Vomiting	MD90	Approved	[187]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[218]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[219]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[220]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[221]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[222]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[223]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[224]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[201]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[225]
Selenium	DM25CGV	N. A.	N. A.	Approved	[158]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[160]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[226]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[227]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[228]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[229]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[99]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[230]

Drug(s) Affected By Proto-oncogene tyrosine-protein kinase Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[231]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[232]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[233]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[234]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[235]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[236]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[236]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]

Drug(s) Affected By Natriuretic peptides B (NPPB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[237]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[238]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[239]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[205]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[241]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[242]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[243]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[244]

Drug(s) Affected By Insulin-like growth factor-binding protein 3 (IGFBP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[245]
Selenium	DM25CGV	N. A.	N. A.	Approved	[246]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[247]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[248]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[204]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[136]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[249]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[250]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[251]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]

Drug(s) Affected By Neurotensin/neuromedin N (NTS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[252]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[253]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[254]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[255]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[256]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[257]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[258]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[18]
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[252]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[259]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[260]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[221]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[261]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[262]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[263]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[264]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[265]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[266]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[267]

Drug(s) Affected By Small ribosomal subunit protein RACK1 (RACK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[268]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[269]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[270]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[104]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[104]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[271]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[272]

Drug(s) Affected By Peroxisome proliferator-activated receptor alpha (PPARA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[273]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[205]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[274]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[275]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[276]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[99]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[277]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[278]

Drug(s) Affected By Delta(24)-sterol reductase (DHCR24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[202]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[279]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[280]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[188]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[119]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[281]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[104]

Drug(s) Affected By Programmed cell death protein 4 (PDCD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[282]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[283]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[282]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[284]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[234]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[282]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[285]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[101]

Drug(s) Affected By NAD-dependent protein deacetylase sirtuin-1 (SIRT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[286]
Selenium	DM25CGV	N. A.	N. A.	Approved	[202]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[287]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[288]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[289]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[290]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[291]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[285]
Olaparib	DM8QB1D	Ovarian cancer	2C73	Approved	[292]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[293]

Drug(s) Affected By G-protein coupled estrogen receptor 1 (GPER1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[294]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[295]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[108]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[296]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[199]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[199]

Drug(s) Affected By Sulfotransferase 1E1 (SULT1E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[297]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[297]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[298]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[299]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[297]
Dienestrol	DMBSXI0	Atrophic vaginitis	GA30.2	Approved	[299]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[300]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[145]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[301]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[146]

Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[127]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[128]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[133]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[133]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[302]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[137]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[303]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[304]

Drug(s) Affected By Dehydrogenase/reductase SDR family member 11 (DHRS11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[305]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[305]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[306]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[188]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[305]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[307]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[308]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[296]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[309]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[310]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[311]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[312]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[102]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[313]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[314]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[315]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[316]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[317]

Drug(s) Affected By Steryl-sulfatase (STS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[318]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[205]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[318]
Tazarotene	DM8SMD1	Acne vulgaris	ED80	Approved	[319]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[307]
Danazol	DML8KTN	Menorrhagia	GA20.50	Approved	[320]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[319]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[318]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[3]
Glucose-6-phosphate dehydrogenase (G6PD)	TTKN8W0	G6PD_HUMAN	Inhibitor	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 8 (ABCC11)	DTWN7FC	ABCCB_HUMAN	Substrate	[5]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[6]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[7]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Aromatase (CYP19A1)	DEQX145	CP19A_HUMAN	Substrate	[10]
Beta-HSD adrenal and gonadal type (HSD3B2)	DEN0GVQ	3BHS2_HUMAN	Substrate	[11]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[12]
Sulfotransferase 2A1 (SULT2A1)	DE0P6LK	ST2A1_HUMAN	Substrate	[13]
Estradiol 17-beta-dehydrogenase 2 (HSD17B2)	DEBMFZ8	DHB2_HUMAN	Substrate	[14]
Estradiol 17-beta-dehydrogenase 1 (HSD17B1)	DEZS5YK	DHB1_HUMAN	Substrate	[14]
Dihydrotestosterone oxidoreductase (HSD3B1)	DERDQWN	3BHS1_HUMAN	Substrate	[11]
Peroxisomal multifunctional enzyme 2 (HSD17B4)	DEJHG19	DHB4_HUMAN	Substrate	[14]
Sulfotransferase 2B1 (SULT2B1)	DEZBN53	ST2B1_HUMAN	Substrate	[15]
Cytochrome P450 7B1 (CYP7B1)	DE36TMY	CP7B1_HUMAN	Substrate	[16]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)	OT6EBDHM	DHB1_HUMAN	Biotransformations	[14]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Biotransformations	[14]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[17]
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Gene/Protein Processing	[18]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[19]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[19]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Protein Interaction/Cellular Processes	[20]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[21]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[22]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Biotransformations	[22]

References

• [1] Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology. 2005 Nov;146(11):4568-76.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2370).
• [3] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [4] Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
• [5] Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57.
• [6] Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
• [7] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [8] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [9] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [10] Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
• [11] Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
• [12] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [13] Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
• [14] Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
• [15] Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
• [16] CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol--potential role(s) for estrogen signaling. FEBS J. 2008 Apr;275(8):1778-89.
• [17] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [18] Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15.
• [19] Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. FEBS J. 2005 Mar;272(6):1343-53. doi: 10.1111/j.1742-4658.2005.04563.x.
• [20] The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism. J Biol Chem. 1999 Dec 3;274(49):35186-90.
• [21] Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor. Chem Biol Interact. 2013 May 25;203(3):597-603.
• [22] Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
• [23] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [24] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [25] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [26] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [27] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [28] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [29] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [30] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [31] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [32] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [33] Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279)
• [35] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [36] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [37] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [38] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [39] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [40] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [41] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [42] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [43] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [44] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [45] Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
• [46] Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
• [47] ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
• [48] The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
• [49] P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
• [50] Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
• [51] Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
• [52] Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
• [53] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [54] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [55] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [56] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [57] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [58] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [59] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [60] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [61] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
• [62] Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24.
• [63] ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
• [64] MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14.
• [65] Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01725-16.
• [66] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [67] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [68] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [69] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [70] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [71] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [72] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [73] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [74] Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
• [75] Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
• [76] Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
• [77] Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
• [78] N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
• [79] Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
• [80] Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
• [81] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [82] Drug Interactions Flockhart Table
• [83] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [84] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [85] Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
• [86] Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
• [87] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
• [88] Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
• [89] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
• [90] Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
• [91] Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
• [92] Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
• [93] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [94] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [95] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [96] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [97] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [98] SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006 Oct;75(4):605-14.
• [99] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [100] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [101] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [102] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [103] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [104] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [105] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [106] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [107] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [108] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [109] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [110] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [111] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [112] The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
• [113] Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta. Biochem Pharmacol. 2006 Apr 28;71(9):1349-57.
• [114] Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
• [115] Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
• [116] Acetaminophen Modulates the Expression of Steroidogenesis-Associated Genes and Estradiol Levels in Human Placental JEG-3 Cells. Toxicol Sci. 2021 Jan 6;179(1):44-52. doi: 10.1093/toxsci/kfaa160.
• [117] Decreased levels of H3K9ac and H3K27ac in the promotor region of ovarian P450 aromatase mediated low estradiol synthesis in female offspring rats induced by prenatal nicotine exposure as well as in human granulosa cells after nicotine treatment. Food Chem Toxicol. 2019 Jun;128:256-266. doi: 10.1016/j.fct.2019.03.055. Epub 2019 Apr 6.
• [118] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [119] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [120] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [121] Regulation of steroid hydroxylase CYP7B1 by androgens and estrogens in prostate cancer LNCaP cells. Biochem Biophys Res Commun. 2006 Jun 2;344(2):540-6. doi: 10.1016/j.bbrc.2006.03.175. Epub 2006 Apr 4.
• [122] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [123] Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3. Epub 2013 Feb 12.
• [124] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [125] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [126] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [127] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [128] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [129] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [130] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [131] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [132] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [133] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [134] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [135] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [136] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [137] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [138] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [139] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [140] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [141] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [142] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [143] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [144] Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells. Drug Metab Pharmacokinet. 2002;17(1):42-6.
• [145] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [146] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [147] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [148] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [149] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [150] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [151] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [152] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [153] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [154] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [155] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [156] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [157] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [158] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [159] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [160] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [161] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [162] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [163] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [164] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [165] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [166] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [167] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [168] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [169] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [170] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [171] Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
• [172] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [173] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [174] Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab. 2006 Jul;91(7):2696-703.
• [175] Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. Acta Biochim Pol. 2004;51(4):907-17.
• [176] Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2. J Biol Chem. 2008 Mar 14;283(11):6925-34. doi: 10.1074/jbc.M708432200. Epub 2008 Jan 9.
• [177] Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 Mar;46(3):444-8.
• [178] A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
• [179] Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Toxicol In Vitro. 2018 Mar;47:63-71.
• [180] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [181] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [182] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [183] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [184] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [185] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [186] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [187] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [188] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [189] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [190] High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr. 2008 Apr;99(4):703-8.
• [191] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [192] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [193] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [194] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [195] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [196] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [197] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [198] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [199] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [200] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [201] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [202] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [203] Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating and quiescent cells. Int J Toxicol. 2010 May-Jun;29(3):326-35. doi: 10.1177/1091581810366486.
• [204] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [205] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [206] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [207] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [208] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [209] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [210] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [211] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [212] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [213] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [214] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [215] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [216] High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
• [217] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [218] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [219] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [220] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [221] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [222] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [223] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [224] [Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells]. Zhonghua Fu Chan Ke Za Zhi. 2014 Jul;49(7):531-5.
• [225] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [226] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [227] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [228] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [229] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [230] Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J Urol. 2006 Jul;176(1):354-60. doi: 10.1016/S0022-5347(06)00516-7.
• [231] SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
• [232] Selective activation of Src family kinases and JNK by low levels of chromium(VI). Toxicol Appl Pharmacol. 2003 Aug 1;190(3):214-23. doi: 10.1016/s0041-008x(03)00188-1.
• [233] Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
• [234] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [235] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [236] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [237] Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
• [238] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [239] Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J. 2009 Oct;73(10):1965-8. doi: 10.1253/circj.cj-08-0181. Epub 2009 Jan 27.
• [240] Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
• [241] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [242] Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
• [243] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [244] Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J. 2009 Jun;73(6):1067-73. doi: 10.1253/circj.cj-08-1026. Epub 2009 Apr 14.
• [245] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [246] Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells. Biofactors. 2007;31(3-4):155-64. doi: 10.1002/biof.5520310302.
• [247] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [248] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [249] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [250] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [251] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [252] Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells. Regul Pept. 2008 Apr 10;147(1-3):96-109. doi: 10.1016/j.regpep.2008.01.009. Epub 2008 Feb 11.
• [253] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [254] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [255] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [256] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [257] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [258] A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate. 2007 Feb 1;67(2):190-202. doi: 10.1002/pros.20518.
• [259] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [260] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [261] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [262] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [263] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [264] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [265] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [266] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [267] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [268] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [269] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [270] Role of androgens in dhea-induced rack1 expression and cytokine modulation in monocytes. Immun Ageing. 2016 May 29;13:20. doi: 10.1186/s12979-016-0075-y. eCollection 2016.
• [271] The scaffold protein RACK1 is a target of endocrine disrupting chemicals (EDCs) with important implication in immunity. Toxicol Appl Pharmacol. 2017 Jun 15;325:37-47. doi: 10.1016/j.taap.2017.04.011. Epub 2017 Apr 13.
• [272] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [273] The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.
• [274] Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):204-9. doi: 10.1093/abbs/gmq130. Epub 2011 Jan 21.
• [275] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [276] (9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells. Toxicology. 2014 Dec 4;326:18-24.
• [277] Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009 Sep;29(9):3647-58.
• [278] Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011 Jul 15;662(1-3):9-14. doi: 10.1016/j.ejphar.2011.04.043. Epub 2011 May 1.
• [279] Simvastatin modulates the Alzheimer's disease-related gene seladin-1. J Alzheimers Dis. 2012;28(2):297-301.
• [280] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [281] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [282] Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
• [283] Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan;5(1):95-108. doi: 10.1158/1541-7786.MCR-06-0125.
• [284] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [285] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [286] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [287] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [288] The p53/miR-34a/SIRT1 Positive Feedback Loop in Quercetin-Induced Apoptosis. Cell Physiol Biochem. 2015;35(6):2192-202. doi: 10.1159/000374024. Epub 2015 Apr 7.
• [289] AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
• [290] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [291] Hydroquinone-induced malignant transformation of TK6 cells by facilitating SIRT1-mediated p53 degradation and up-regulating KRAS. Toxicol Lett. 2016 Sep 30;259:133-142. doi: 10.1016/j.toxlet.2016.08.006. Epub 2016 Aug 8.
• [292] Iron overload inhibits cell proliferation and promotes autophagy via PARP1/SIRT1 signaling in endometriosis and adenomyosis. Toxicology. 2022 Jan 15;465:153050. doi: 10.1016/j.tox.2021.153050. Epub 2021 Nov 23.
• [293] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [294] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [295] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [296] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [297] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [298] Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
• [299] Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase. Anal Biochem. 2006 Oct 1;357(1):85-92.
• [300] Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro. Drug Metab Dispos. 2003 Nov;31(11):1300-5.
• [301] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [302] Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
• [303] Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
• [304] Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
• [305] Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
• [306] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [307] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [308] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [309] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [310] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [311] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [312] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [313] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [314] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [315] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [316] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [317] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [318] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [319] Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J Cell Biochem. 2006 Feb 1;97(2):327-50. doi: 10.1002/jcb.20579.
• [320] Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzyl-inhibiting group. Eur J Med Chem. 2001 Jul-Aug;36(7-8):659-71. doi: 10.1016/s0223-5234(01)01262-4.